Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction.
CDK4/6 inhibitor
Drug-drug interactions
HPLC-MS/MS
Metastatic breast cancer
Therapeutic drug monitoring
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
05 Sep 2020
05 Sep 2020
Historique:
received:
13
05
2020
revised:
16
06
2020
accepted:
18
06
2020
pubmed:
6
7
2020
medline:
22
6
2021
entrez:
6
7
2020
Statut:
ppublish
Résumé
The CDK4/6 inhibitors palbociclib and ribociclib are kinase inhibitors used in association with hormonal therapy for the management of patients with metastatic breast cancer. Like most kinase inhibitors, therapeutic drug monitoring may be used for personalize their dosage. To this aim, we developed and validated a sensitive and specific HPLC-MS/MS method for palbociclib and ribociclib quantification in blood samples. We then quantified exposure to palbociclib (plasma trough concentration; C
Identifiants
pubmed: 32623316
pii: S0731-7085(20)31324-8
doi: 10.1016/j.jpba.2020.113438
pii:
doi:
Substances chimiques
Benzimidazoles
0
Pharmaceutical Preparations
0
Protein Kinase Inhibitors
0
CDK4 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
Cyclin-Dependent Kinase 6
EC 2.7.11.22
Banques de données
ClinicalTrials.gov
['NCT04025541']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113438Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest No competing interests to declare for all authors/provided financial support for the conduct of the research